Smad4/DPC4
The DOI matches its Crossref record; 52 of the 56 references it cites were found in a registry or an index.
Abstract
Smad4 or DPC4 belongs to a family of signal transduction proteins that are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor beta (TGF-β) signaling via several pathways. The gene acts as a tumour suppressor gene and inactivation of smad4/DPC4 is best recognised in pancreatic cancer. However, smad4/DPC4 is also mutated in other conditions and cancers such as juvenile polyposis syndrome with and without hereditary haemorrhagic telangiectasia, colorectal and prostate cancers. Immunohistochemistry for smad4/DPC4 protein is most useful in separating benign/reactive conditions from pancreatic cancer in needle/core biopsies. In normal and reactive states, the protein is localised to the cytoplasm and nucleus, while the protein is lost in high-grade pancreatic intraepithelial neoplasia/carcinoma in situ and pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study involving 249 PDAC patients revealed that 43% lacked SMAD4 expression and 45% were positive.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
In the citing paper
“In pancreatic cancer, its inactivation is common, with immunohistochemistry effectively distinguishing benign from malignant states.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
In the citing paper
“Smad4/DPC4, activated by TGF-β signaling, acts as a tumor suppressor gene.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
In the citing paper
“Patients with intact SMAD4 expression exhibited significantly improved prognosis, with a median survival of 19.2 months compared to 14.7 months for those lacking SMAD4 [66,82].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
In the citing paper
“Genetic analysis showed concordance between SMAD4 expression and genetic status in 97% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [82]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
Molecular Genetics of Colorectal Cancer
Fearon, E. R. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130235 · Cited by 1,805
DPC4 gene in various tumor types.
Schutte, M. E. M., Hruban, R. H., Hedrick, L., Cho, K. R., Nadasdy, G. M., Weinstein, C. L., Bova, G. S., Isaacs, W. B., Cairns, P., Nawroz, H., et al. (1996) · PubMed · Cited by 672
Wilentz, R. E., Iacobuzio–Donahue, C. A., Argani, P., McCarthy, D. M., Parsons, J. L., Yeo, C. J., Kern, S. E., & Hruban, R. H. (2000) · PubMed · Cited by 591
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Ding, Z., Wu, C.-J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J., Perry, S. R., Labrot, E. S., Wu, X., Lis, R., et al. (2011) · Nature · doi:10.1038/nature09677 · Cited by 515
Dual role of the Smad4/DPC4 tumor suppressor in TGFβ-inducible transcriptional complexes
Liu, F., Pouponnot, C., & Massagué, J. (1997) · Genes & Development · doi:10.1101/gad.11.23.3157 · Cited by 445
Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis
Miyaki, M., Iijima, T., Konishi, M., Sakai, K., Ishii, A., Yasuno, M., Hishima, T., Koike, M., Shitara, N., Iwama, T., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202642 · Cited by 436
The genomic landscape of small intestine neuroendocrine tumors
Banck, M. S., Kanwar, R., Kulkarni, A. A., Boora, G. K., Metge, F., Kipp, B. R., Zhang, L., Thorland, E. C., Minn, K. T., Tentu, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67963 · Cited by 324
Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
Roth, A. D., Delorenzi, M., Tejpar, S., Yan, P., Klingbiel, D., Fiocca, R., d'Ario, G., Cisar, L., Labianca, R., Cunningham, D., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs427 · Cited by 284
Research works printed but not linked: 1
- 10.1002/1097-0142(20010401)91:7<1332::aid-cncr1136>3.0.co;2-4 · doi:10.1002/1097-0142(20010401)91:7<1332::aid-cncr1136>3.0.co;2-4
Cited by
Zheng, L., Liang, H., Zhang, Q., Shen, Z., Sun, Y., Zhao, X., Gong, J., Hou, Z., Jiang, K., Wang, Q., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01495-y · Cited by 159
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
Driver Gene Mutations and Epigenetics in Colorectal Cancer
Raskov, H., Søby, J. H., Troelsen, J. T., Bojesen, R. D., & Gögenür, I. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003393 · Cited by 107
Fang, T., Liang, T., Wang, Y., Wu, H., Liu, S., Xie, L., Liang, J., Wang, C., & Tan, Y. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01864-9 · Cited by 66
Metadata
- Authors
- McCarthy, A. J., & Chetty, R.
- Affiliations
- University Health Network (CA)
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2018-05-02
- Volume
- 71
- Issue
- 8
- Pages
- 661-664
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W4229972630
- Cited by
- 71
- References
- 56
- Citations by year
- 2026: 1 · 2025: 12 · 2024: 11 · 2023: 12 · 2022: 12 · 2021: 16 · 2020: 2 · 2019: 3 · 2018: 2
- FWCI
- 0.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Pathology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Keywords
- SMAD4, tumor suppressor, TGF-beta signaling, pancreatic cancer, pancreatic intraepithelial neoplasia, carcinoma in situ, juvenile polyposis syndrome, hereditary hemorrhagic telangiectasia, colorectal cancer, prostate cancer, immunohistochemistry, core needle biopsy, protein localization
- MeSH terms
- Animals, Humans, Mutation, Neoplasms, Biomarkers, Tumor, Signal Transduction, Gene Expression Regulation, Neoplastic, Smad4 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Smad4/DPC4. https://app.cochat.ai/papers/10.1136/jclinpath-2018-205095
- The paper
- McCarthy, A. J., & Chetty, R. (2018). Smad4/DPC4. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2018-205095
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.